In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdAlta Ltd.

adalta.com.au

Latest From AdAlta Ltd.

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Deals M & A

Ossianix Cracks Open The Blood-Brain Barrier

By using the binding region of shark antibodies as a carrier to cross the blood-brain barrier, Ossianix reckons it has made significant progress against an issue that has held back the development of CNS-active neurological therapies.

Platform Technologies Research & Development

AdAlta CEO On Shark Antibody Technology

AdAlta CEO Sam Cobb discusses development of the company's novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.

StartUps and SMEs Research & Development

Appointments: Gilead, Biogen, Nordic Nanovector, Neon Therapeutics, Achaogen and vasopharm

This week's roundup includes executive appointments by Gilead Sciences, Nordic Nanovector, Mereo BioPharma, vasopharm and Rigontec. Biogen has also appointed two executives to its planned spin-off company, Bioverativ.

Appointments
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • AdAlta Ltd.
  • Senior Management
  • Tim Oldham, Managing Dir. & CEO
    Michael Foley, PhD, CSO
  • Contact Info
  • AdAlta Ltd.
    Phone: 9479 5159
    15/2 Park Drive
    Melbourne, 3083
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register